semaglutide news october 16 2025 Ozempic's Patent Protection Starts to Expire in 2026. What Next? Semaglutide: Shedding pounds, weighing risks

Pharmaceutics 18 , 787795 (2021)

Reviewed by Tamar Rodney, PhD, PMHNP-BC, CNE, Mental Health Nurse Practitioner

Participants received orforglipron at doses of 6, 12, or 36 mg (which correspond to the current 5.5, 14.5, and 17.2 mg maintenance doses) or placebo, alongside diet and exercise counselling, for 72 weeks

RESEARCH GRADE

3,55,6668 Several large population-based studies have also shown an association between elevated TSH levels and higher risk of incident CKD and CKD progression, 41,42,69 an in one rigorous study of non-dialysis dependent CKD (NDD-CKD) patients with subclinical hypothyroidism, those treated with exogenous thyroid hormone replacement had an amelioration of eGFR decline over time

some heat or tingling as well as my downtime after each treatment